Sir Demis Hassabis, founder and CEO of Isomorphic Labs, delivering his Nobel Lecture in Stockholm

Isomorphic Labs Raises $5B Series C to Push AI-Designed Drugs Toward Clinical Trials

Isomorphic Labs has raised $5 billion in Series C funding to move its first AI-designed medicines toward human trials. Greenoaks and Sequoia Capital co-led the oversubscribed round, which the company announced on 17 November.

Andreessen Horowitz joined as a new investor, alongside other new backers, while Alphabet made another significant investment. Every existing investor returned, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company did not disclose a valuation.

Isomorphic Labs artwork showing AI-designed molecules
Isomorphic Labs is scaling its IsoDDE drug design engine with the new capital.

What the money will fund

The capital will advance IsoDDE, the drug design engine at the heart of the company, and scale its pipeline of medicine candidates. Isomorphic will also build the global infrastructure needed for AI-led bioengineering and develop its clinical and translational teams.

IsoDDE brings together foundational simulation models that work across therapeutic areas and drug types. The system explores vast chemical spaces to design molecules, predict their properties and refine them before scientists choose which ones to make and test.

Isomorphic says its models are already producing positive preclinical results in oncology and immunology, both in its own programmes and with partners. The company describes that progress as setting the stage for clinical entry, though no candidate has entered human trials yet.

“Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress.”
Sir Demis Hassabis, Founder and CEO of Isomorphic Labs

A fast follow to the Series B

The Series C lands about six months after Isomorphic raised $2.1 billion in a Series B led by Thrive Capital in May. Its first external round, $600 million, closed in March 2025. The three rounds together total $7.7 billion.

Built on AlphaFold

Isomorphic was founded in 2021 as a spinout of Google DeepMind. Its work builds on AlphaFold, the DeepMind system that predicts protein structures and won its creators the 2024 Nobel Prize in Chemistry.

The company is led by founder and chief executive Sir Demis Hassabis, with Max Jaderberg as president. It is headquartered in London, with offices in Cambridge, Massachusetts and Lausanne, Switzerland.

Its partners include Novartis, Eli Lilly and Johnson and Johnson. The company runs both partnered programmes and its own internal pipeline of drug candidates.

You can follow more AI funding rounds on our funding tracker.

Leave a Comment

Professor Derpy's Notes

Isomorphic raised $5 billion so AI can design medicines. I believe the fastest cure is a computer doing chemistry while I supervise from the sofa.

Join our newsletter

email subscription

Receive Latest AI Insights To Your Inbox